Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
956 people get SNTA articles and Market Currents by email alert.
Get email alerts on SNTA »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
Synta Readying 2 Key Lung Cancer TrialsLen Zehr • Wed, Apr 20, 2011 -
Putting a Price Tag on Synta's Lead Drug ActivitiesOhad Hammer • Sun, Mar 20, 2011
-
-
-
-
Evaluating Synta Pharmaceuticals' CashflowBrian Orelli • Mon, Mar 26, 2007 -
Recent IPO Synta Pharma Sees Strong Insider BuyingRichard Shonfeld • Tue, Feb 27, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5 Healthcare Companies With Significant Recent Insider Buying (Part IV)Markus Aarnio • Wed, Nov 14, 2012
-
Investments In The Fight Against Cancer: The Analysts' ChoicesGlen S. Woods • Mon, Nov 5, 2012 -
-
-
-
-
Synta Pharmaceuticals Corp. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Synta Pharmaceuticals Corp. Q3 2009 Earnings Call TranscriptWed, Nov 4, 2009
-
Synta Pharmaceuticals Corp. Q3 2008 Earnings Call TranscriptThu, Nov 13, 2008
-
Synta Pharmaceuticals Corp. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Synta Pharmaceuticals Corp. Q1 2008 Earnings Call TranscriptTue, May 27, 2008
-
Synta Pharmaceuticals Corp. Q4 2007 Earnings Call TranscriptThu, Mar 20, 2008
-
Business Wire (Jun 4, 2013)
-
Business Wire (May 31, 2013)
-
Business Wire (May 15, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 5, 2013)
-
Business Wire (Mar 14, 2013)
-
Business Wire (Mar 13, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 11, 2013)
-
Business Wire (Dec 13, 2012)
-
Business Wire (Dec 12, 2012)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 26, 2012)
-
Business Wire (Nov 9, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 6, 2012)
-
Business Wire (Oct 24, 2012)
SNTA vs. ETF Alternatives
Company Description
Currently, there's no company description for SNTA.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Friday, June 7, 9:11 AM
Premarket gainers: ROSG +16%. JKS +15%. IMUC +10%. NLST +8%. CBK +8%. GFA +7%. SNTA +7%. ELN +5%.
Losers: FSGI -42%. TIVO -18%. IRM -15%. JRCC -14%. LAMR -9%. CPRT -8%. FRO -7%. EQIX -8%. OIS -8%. Comment! [On the Move] - Thursday, June 6, 7:37 PM Synta Pharmaceuticals (SNTA) regains a big chunk in post-trading of what it lost during the regular session, after CEO Safi R. Bahcall discloses the purchase of 10K shares at $4.40. The insider buy follows the 70% hit the stock took following survival results from its Phase 2b/3 trial of Ganetespib presented at as ASCO last week. In addition to Bahcall's purchase, Director and larger shareholder Bruce Kovner also recently disclosed the purchase of 2M shares. Shares +4.9% AH. 1 Comment [Healthcare, On the Move]
- Thursday, June 6, 4:20 PM Synta Pharmaceuticals (SNTA) has another tough day, falling 5.86% in regular trading, even as CEO Dr. Safi Bahcall gives what might fairly be described as an upbeat presentation at the Jefferies Global Healthcare Conference on the ongoing GALAXY trials for ganetespib (webcast). Despite company rhetoric, the market seems to be laser-focused on an increased Hazard ratio from one study to the next (I, II), something which has weighed heavily on the shares all week. 3 Comments [Healthcare, On the Move]
-
Thursday, June 6, 12:45 PM
Midday top 10 gainers: OSH +29%. SKBI +25%. MEG +23%. RDCM +19%. TRUE +16%. NPTN +13%. CIEN +13%. TRMD +13%. MY +12%. FSGI +11%.
Midday top 10 Losers: PAY -19%. CBAK -15%. SNTA -14%. CWTR -13%. GIG -12%. ASNA -11%. RST -10%. VRA -10%. FRAN -9%. YOD -9%. Comment! [On the Move] - Tuesday, June 4, 2:40 PM Synta Pharmaceuticals (SNTA +2.7%) moves up today, after the company announced earlier that it will be presenting at the Jefferies 2013 Global Healthcare Conference on Thursday, June 6, in New York. Comment! [Healthcare, On the Move]
- Monday, June 3, 2:35 PM Synta Pharmaceuticals (SNTA -34.1%) plummets as the market's interpretation of results from a Phase 2b/3 trial of the Hsp90 inhibitor ganetespib is far less sanguine than the company's own take on the data. SNTA notes that "the combination of ganetespib plus docetaxel improves overall, and progression-free-survival compared to docetaxel alone," but investors seem to be focused on an increase in the Hazard ratio from results reported last fall. In short: data now suggest an 18% reduction in the risk of death compared to a 31% reduction last September. (previous) 1 Comment [Healthcare, On the Move]
- Monday, June 3, 12:48 PM Midday top 10 gainers: CLVS +124%. OSH +62%. FALC +35%. TSRO +31%. ASI +21%. CHTP +19%. RCPT +18%. FLML +17%. LPTH +17%. PXLW +16%. Midday top 10 Losers: SNTA -34%. INFI -26%. SCON -20%. AFFY -19%. NBG -15%. GIGA -12%. P -11%. XONE -10%. DQ -10%. PW -10%. Comment!
-
Monday, June 3, 9:13 AM
Premarket gainers: ASI +21%. TEAR +11%. PPHM +12%. OSH +9%. CLP +7%. MTL +6%. SODA +5%. INFY +5%.
Losers: AFFY -27%. INFI -16%. NBG -13%. SNTA -12%. Comment! [On the Move] - Monday, June 3, 8:43 AM Synta Pharmaceuticals' (SNTA) Ganetespib helped extend the lives of lung-cancer patients to a median 9.8 months when used with chemotherapy in a Phase II trial vs 7.4 month with subjects that were given just chemo. While shares are +8.4%, The Street's Adam Feuerstein says the trial results were "not statistically significant and (were) worse than" an update from study last September. (PR) 1 Comment [Healthcare, On the Move]
-
Wednesday, May 8, 12:53 PM
Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move] -
Tuesday, May 7, 12:52 PM
Midday top 10 gainers: FSGI +28%. ARCI +27%. ININ +18%. MELI +18%. NLS +18%. PRTS +18%. REED +16%. PODD +14%. LAS +12%. MKTG +12%.
Midday top 10 losers: DCO -27%. RKUS -25%. GNK -24%. CUTR -23%. ARUN -22%. SNTA -15%. AMRI -12%. PIKE -12%. TA -12%. PTRY -11%. Comment! [On the Move] - Tuesday, April 30, 6:57 AM Synta Pharmaceuticals (SNTA): Q1 EPS of -$0.30 misses by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, March 14, 8:00 AM Synta Pharmaceuticals (SNTA): Q4 EPS of -$0.29 misses by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, December 13, 2012, 12:24 PM Synta Pharmaceuticals (SNTA +3.6%) trades up after saying it's entered into stock purchase agreements with members of its Board and various institutional investors to sell 7M shares of its common stock in an issuer directed, registered direct offering. Shares were priced at $8.60, yesterday's closing bid price. Gross proceeds from the sale were approximately $60M. Comment! [Healthcare, On the Move]
-
Monday, November 12, 2012, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD +8.1%.
After-hours top losers: INFI -8.6%. SCLN -5.5%. EVER -4.4%. GME -4.1%. MWE -3.7%. Comment! [On the Move] -
Monday, October 1, 2012, 12:45 PM
Midday top 10 gainers: CRDN +43%. FONR +34%. BIOF +19%. VSR +17%. MTG +16%. SNTA +16%. VSNT +15%. PATK +14%. MGI +12%. SFUN +12%.
Top 10 Losers: NC -65%. TYC -49%. GMAN -24%. BYFC -17%. THLD -17%. PPHM -16%. GNI -11%. OCZ -10%. ROSG -10%. CYTX -8%. 1 Comment [On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Joshua Hayes
Big Wave Trading Portfolio Update And Top Current Holdings http://bit.ly/LEAhD2 SNTA FU MAGS VRNM BVSN PHMD AVD ANGI - View all 0 replies
-
- View all 5 replies
-
tuliptown: am long as well. What does the HUGE volume down mean to you? Who were the weak hands leaving and who are buying? agree data was good. -
-
TruffelPig
SNTA: I did read the data - they were actually pretty good; progression free time at least doubled, in some groups tripled - View all 3 replies
-
TruffelPig: Something similar happened to ECYT end of last year - the "expert" investors also sold and were WRONG.
-
TruffelPig: As a biochemist I pressed the buy button today! Price target $10 in the next 12 month. Good story.
-
- View all 0 replies
-
Jim Van Meerten
SNTA - 72% Barchart technical buy signal - 12 new highs and up 49.68% in the past year 0 Relative strength Index 72.23% - View all 1 replies
-
LATEST REPLIES
-
- View all 5 replies
-
tuliptown: am long as well. What does the HUGE volume down mean to you? Who were the weak hands leaving and who are buying? agree data was good.
-
-
TruffelPig
SNTA: I did read the data - they were actually pretty good; progression free time at least doubled, in some groups tripled - View all 3 replies
-
TruffelPig: Something similar happened to ECYT end of last year - the "expert" investors also sold and were WRONG.
-
TruffelPig: As a biochemist I pressed the buy button today! Price target $10 in the next 12 month. Good story.
-
Jim Van Meerten
SNTA - 72% Barchart technical buy signal - 12 new highs and up 49.68% in the past year 0 Relative strength Index 72.23% - View all 1 replies
-
-
Todd Theman
Looking for an entry point into SNTA. Is $4 reasonable? Looking for a bump in advance of ASCO this summer. - View all 1 replies
-
PYRAMIDHUNT: An insider bought $5,000,000 of shares at $4.40 just a couple months ago.
-
The Scientist
Market potential for SNTA ganetespib is ridiculous. If it works in half the cancers they are studying, $10B+ potential. - View all 8 replies
-
-
The Scientist: I am a MD, PhD. I used to spend all my time in a molecular biology lab. Now I practice medicine.